Pharmaceutical neocolonialism: when patents are worth more than lives

“All human beings are equal.” But when it comes to health, that equality disappears. The life of a European child is worth more—in practice, not just in words—than that of an African child. The life of a patient in Switzerland is worth more than that of a farmer in Bolivia.

They don't say it out loud, but they show it through their decisions. And the tool of that inequality isn't an army or an invasion: It's the international pharmaceutical industry and the patent system that protects it as if it were a sacred temple.

Pharmaceutical neocolonialism is the power to decide who receives a medicine, who waits, who suffers, and who dies.

---

How does this colonialism work?

It works like classic colonialism: The North accumulates benefits and the South pays with its body.

But now the loot is not gold or oil: It is human health.

Patents as trade weapons

A patent should protect research. But today it's used to block production, raise prices, and maintain a monopoly.

When a pharmaceutical company obtains a patent for a drug:

• Control who manufactures it.

• Who buys it.

• Who sells it?

• Who can access it.

  
  

For 20 years or more, no country can produce a generic version without being penalized by the World Trade Organization. What should be a scientific advancement becomes an instrument of subjugation.

Price as a barrier to entry

A cancer treatment that costs $100 to manufacture can be sold at:

• $3,000 in Europe.

• 10,000 in Latin America.

• 30,000 in African countries that cannot produce it and must import it.

  
  

The price does not reflect the true cost of the medication. It reflects the cost of maintaining the privilege.

Structural dependency

Southern countries cannot produce their own medicines because:

• Lack of infrastructure.

• Lack of technology transfer.

• Patent prohibitions.

• Dependence on imports.

• World Bank conditions.

  
  

It's the same old colonial logic: I make you addicted and then I sell you the cure.

What do they gain by controlling health?

They achieve exactly what colonial empires sought: economic, political, and moral control.

Governments obliged to obey

A country that depends on the Global North for vaccines, antibiotics, HIV treatments, insulin, or cancer medications is a country incapable of making sovereign decisions. It may have political independence, but not biological independence.

The threat doesn't need rifles: simply cutting off the supply of medicines is enough.

A guaranteed market

Southern countries account for more than 80% of the world's diseases … But barely 20% of the pharmaceutical market .

That is to say:

• They are the ones who need medicine the most.

• But those who can least afford them.

  
  

The industry ensures itself a perpetual customer: sick, poor, and without alternatives.

A moralistic discourse to justify inequality

It is repeatedly stated that manufacturing medicines in the Global South “is not safe,” “is not ethical,” and “does not meet standards.” The narrative is constructed that the Global North “protects quality” when in reality it is protecting its market reserves.

It's health racism disguised as a regulation.

How do they set their traps?

The traps are not in the laboratories: they are in international laws, trade agreements, and multilateral institutions.

Trap 1: The WTO TRIPS Agreement

This agreement obliges all countries to respect pharmaceutical patents. If a country produces a cheaper generic drug, it can be financially sanctioned by the World Trade Organization.

The trap: “I’ll let you get sick, but I won’t let you get better unless you pay.”

Trap 2: “Medical aid” that destroys local production

When massive donations of medicines or vaccines arrive, local producers go bankrupt. Once they disappear, the country becomes completely dependent on the North.

The model is perverse: "I'm giving you medicine today so that you'll depend on me tomorrow."

Trap 3: Clinical trials in the South

Millions of people in Africa and Latin America serve as test subjects for experimental vaccines, new treatments, and corporate-sponsored studies. Once the drug is developed, it returns to the country… but at a price its own population cannot afford.

The trap: “Your body is the factory for my drugs, but you won’t have access to them.”

Trap 4: Biotechnological blackmail

During the pandemic, several countries attempted to produce their own vaccines. Pharmaceutical companies blocked technology transfer, access to formulas, the export of supplies, and emergency licenses.

The trap: “You don’t own the lives of your people; you own my patents.”

The pandemic as a mirror of horror

COVID was the ultimate proof of pharmaceutical neocolonialism.

Vaccine hoarding

Europe stockpiled enough doses to vaccinate its population three times over. The United States stored millions unused. Africa, with 1.3 billion people, barely had access to 2% of the first vaccines.

The refusal to release patents

South Africa and India called for a temporary release of patents on the vaccine to save lives. The United States, the United Kingdom, and the European Union blocked the proposal.

They chose to maintain intellectual property rights… even though thousands died every week.

The failure of the COVAX mechanism

They promised fairness. But they sent surpluses. COVAX wasn't a humanitarian instrument: it was an instrument for maintaining the global order.

Conclusion:

Pharmaceutical neocolonialism demonstrates that capitalism has a moral limit: human life. And that global public health is not guided by ethics or compassion, but by:

• Intellectual property.

• Trade monopolies.

• Agreements designed to protect profit.

• An implicit racism that determines who can wait and who cannot.

  
  

As long as medicines remain a business and not a right, life in the South will continue to be in the hands of the boards of directors in the North.

It's not just unfair. It's downright inhumane.

---

Glossary:

TRIPS (Triple-Associated Trade-Related Aspects of Intellectual Property Rights) — Acronym for the Agreement on Trade- Related Aspects of Intellectual Property Rights. It is a WTO treaty that establishes minimum standards for intellectual property and, according to the text, hinders the production of inexpensive medicines.

COVAX — Acronym for COVID-19 Vaccines Global Access . It was a global initiative led by the WHO and other alliances to ensure equitable access to COVID-19 vaccines, criticized in the article for its ineffectiveness in supplying the Global South.

Clinical trial — A research study conducted with human patients to evaluate the safety and efficacy of a new drug. The text denounces that these trials are often conducted in the Global South to develop medicines that their inhabitants then cannot afford.

Generic drug — A medication created to be the same as a brand-name drug already on the market in terms of dosage, safety, and quality, but much cheaper. Its production is usually restricted by existing patent laws.

WTO — World Trade Organization. It is the only international organization that deals with the rules governing trade between countries and sanctions those who violate patent agreements.

Patent — An exclusive right granted for an invention, allowing its holder to decide whether and how the invention can be used by others. In the pharmaceutical industry, it grants a monopoly on commercial exploitation (usually for 20 years) that keeps prices high.

Global South — A term used to refer to the regions of Latin America, Asia, Africa, and Oceania. It is used to describe countries that, regardless of their strict geographic location, share a history of colonialism and economic inequality vis-à-vis the "Global North" (Europe, the U.S.).